Spectrum of Mutations in *WFS1* Gene in Six Families with Wolfram Syndrome: Identification of Five Novel Mutations

Gupta D1*, Bhai P2, Saxena R1, Bijarnia-Mahay S1, Puri RD1, Verma IC1, Das L1, Bhanisali A2 and Shanker V2

1Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, India
2Department of Endocrinology, PGIMER, Chandigarh, India

**Abstract**

**Background:** Wolfram syndrome is a neurodegenerative disorder characterized by the acronym DIDMOAD (Diabetes Insipidus (DI), Diabetes Mellitus (DM), Optic Atrophy (OA) and Deafness). Homozygous/compound heterozygous mutations in *WFS1* gene causes autosomal recessive form of Wolfram syndrome (AR-WS) whereas heterozygous mutations are associated with autosomal dominant-low-frequency non-syndromic hearing loss (AD-LFNSHL). Clinical symptoms and degree of severity is reported to be heterogeneous in WS patients.

**Aim:** To characterize clinical features and molecular gene mutations in patients with WS in India and compare them with data from other countries.

**Patients and Methodology:** Eleven patients from 6 families were enrolled. In nine patients from 4 families with phenotypic features of diabetes mellitus, optical atrophy and hearing loss *WFS1* gene was sequenced. Two patients of the other 2 families presented with hearing loss only and were analysed for targeted deafness genes panel by next generation sequencing.

**Results:** Nine patients from 4 families had biallelic mutations in *WFS1* gene. Two patients harboured heterozygous mutation in *WFS1* gene. Seven different mutations *WFS1* were identified, of which 5 mutations were novel. All the identified mutations were present in exon 8 of *WFS1* gene.

**Conclusion:** Pathogenic variations in *WFS1* gene can cause both AR-WS and AD-LFNSHL. We recommend a protocol in which patients with WS should be first sequenced for the hotspot exon 8. If no mutation is identified, then the full gene should be sequenced. Further, for patients with hearing loss with/without diabetes and/or optical atrophy, *WS* should be considered as one of the differential diagnosis.

**Keywords:** Wolfram Syndrome (WS); Non-syndromic hearing loss (AD-LFNSHL); *WFS1* gene; Mutation; Hotspot

**Introduction**

Wolfram syndrome (WS) is a neurodegenerative disorder characterized by features denoted by the acronym DIDMOAD (Diabetes Insipidus (DI), Diabetes Mellitus (DM), Optic Atrophy (OA) and Deafness). Although diabetes and optic atrophy comprise the minimal diagnostic criteria, patients may present with neurological, urological and psychiatric manifestations later in their life [1,2]. The prevalence is approximately 1 in 1,00,000 for WS, with a carrier frequency of 1 in 354 in the UK and 1 in 100 in the North American population [3-5].

Genetic mutations in *WFS1* gene cause both recessive and dominant forms of WS. Homozygous or compound heterozygous mutations in *WFS1* gene cause autosomal recessive form of Wolfram syndrome (WS), and heterozygous mutation in one of the alleles is associated with autosomal dominant WS like syndrome [6,7]. Several other, *WFS1*-related disorders have been described such as low-frequency non-syndromic hearing loss (LFNSHL) with autosomal dominant transmission [8]. Mutations in the *WFS1* gene are also implicated in autosomal dominant DM, with OA (11), with DM and OA together, with HL and OA and psychiatric problems [6-16].

*WFS1* gene is mapped on chromosome 4p16 and spans 33.4-kb of genomic DNA. It has eight exons, of which the first exon is non-coding. This gene encodes a transmembrane glycoprotein called wolframin (890 amino acid long), located primarily in the endoplasmic reticulum (Figure 1). This protein is ubiquitously expressed in brain, pancreas, heart, and insulinoma beta-cell lines [5]. Its function has not been fully characterised, but it is reported to have a crucial role in the regulation of Na+/K+ ATPase β-1 subunit, regulation of Ca2+ homeostasis, negative regulation of ER stress and the regulation of insulin biosynthesis and secretion in pancreatic β-cells [17-21].

Different types of mutations, including missense, out of frame or in frame deletions, nonsense and splicing are reported in patients with WS. Majority (80-90%) of the mutations are inactivating and reside in exon 8 [22]. There is a paucity of data on genetic studies in WS in India [23]. We report series of eleven cases from six families, diagnosed to have WS by identification of underline genetic cause in *WFS1* gene.

**Materials and Methods**

**Patients**

Eleven probands from 6 families were enrolled in the study. Blood samples were collected from patients and parents (if available), after

---

*Corresponding author: Dr. Deepti Gupta, Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, India, Tel: +91 11-2575000; E-mail: deepgupta_260885@yahoo.co.in

Received October 22, 2018; Accepted November 10, 2018; Published November 14, 2018

Citation: Gupta D, Bhai P, Saxena R, Bijarnia-Mahay S, Puri RD, et al. (2018) Spectrum of Mutations in *WFS1* Gene in Six Families with Wolfram Syndrome: Identification of Five Novel Mutations. J Mol Genet Med 12: 380 doi:10.4172/1747-0862.1000380

Copyright: ©2018 Gupta D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
obtaining an informed consent from the parents/guardian. Ethical clearance was obtained from the Ethics Committee of Sir Ganga Ram Hospital, New Delhi. Detailed information about age of onset of symptoms, clinical presentation, and family history was collected.

**Molecular analysis of WFS1 gene**

DNA was isolated from leukocytes using standard methods [24]. Coding regions as well as exon–intron boundaries of the hotspot exon 8 of WFS1 genes was amplified by polymerase chain reaction (PCR) for families F1, F2, F3 and F4. Exon 8 (~2.6 Kb), was amplified in four PCR fragments using four sets of primers designed using web primer software (http://www.yeastgenome.org/cgi-bin/web-primer) (sequence available on request). Thermal profile was as follows: initial denaturation at 95°C for 5min, cycle denaturation 95°C for 1min, annealing at 60°C for 1 min, elongation at 72°C for 1min 30 sec (for 35 cycles), final elongation at 72°C for 7min. Amplified PCR products were purified and sequenced using BigDye Terminator sequencing kit and 3500 genetic analysers (Thermo Fisher Applied Biosystems, Foster city, CA, USA) according to the manufacturer’s protocol. Chromatograms obtained after sequencing were analysed using the Chromas pro software (Technelysium.com.au) and matched to the wild type WFS1 (NM_006005) gene sequence. Mutations were classified as novel, if not earlier reported in dbsnp, HGMD, ExAc, 1000 genome, Clinvar and LOVD databases.

**Figure 1:** Hypothetical structure of the wolframin describing the transmembrane domains in the ER (Endoplasmic reticulum) membrane and amino terminal (in cytoplasm) and carboxy terminal domain of the protein in ER lumen.

**Figure 2:** Pedigree charts of wolfram families enrolled labeled as F-1 to F-6. Families (F-1 to F-4) were autosomal recessive WS while families (F-5 and F-6) were autosomal dominant - low-frequency non-syndromic hearing loss (AD-LFNSHL).
Affected children of family F5 and F6 had bilateral sensorineural hearing loss alone, with no other significant phenotypic feature (Table 1). In view of this, targeted deafness gene panel (involving more than 300 genes) was performed using next generation sequencing platform for both the samples. The raw data output files were analyzed for the putative genetic variants using standard Bioinformatics pipeline including base calling, alignment of reads to GRCh37/hg19 genome assembly, primary filtering out of low-quality reads and probable artefacts, and subsequent annotation of variants. All variants related to the phenotype of the proband, except benign or likely benign variants were further evaluated. Heterozygous variant in \textit{WFS1} gene was identified in both the families, also confirmed by Sanger sequencing.

![Chromatograms pictures of the families (F1-F-5) of wolfram syndrome. Chromatograms could not be made available for family F-6. 3A: Chromatograms of both the probands of family F-1.](image)

![Chromatograms of both the probands of family F-2.](image)

![Chromatograms of both the probands of family F-3.](image)
Annotation of novel variations

In silico tools like PolyPhen2, SIFT, Mutation Taster, LRT, Mutation Assessor and FATHMM were used to predict the effect of novel variations (Table 2) [25-30]. Conservation of the amino acids in case of missense change was checked in the homologous protein of different species by multiple sequence alignment using Clustal-Omega web server [31]. Segregation analysis was done where ever possible.

Results

Nine patients from 4 families (F1-F4) met the minimal diagnostic criteria of hearing loss, optic atrophy and diabetes mellitus. Diabetes insipidus was present in 7 patients from 3 families (F2, F3 and F4). Bi-allelic mutations in WFS1 gene were identified in these patients, confirming a diagnosis of autosomal recessive WS.

Affected probands of family F5 and F6 had no phenotypic features of WS other than deafness. Heterozygous mutation was identified in WFS1 gene in these patients, confirming diagnosis of autosomal dominant low frequency non-syndromic hearing loss (LFNSHL). Clinical details are set out in Table 1. Pathogenic variants were identified in all 11 probands of 6 families. Eight different mutations were detected of which 6 were novel. All the identified mutations were present in exon 8 of WFS1 gene (Figure 2).

In family F1, both the probands were compound heterozygous for two novel pathogenic variants in WFS1 gene (Figure 3A). One was a
nonsense change (c.2265T>A; p.Cys755Ter) and the other variation (c.1228_1231delCTCT, p.Val412SersTer29) was a deletion of 4 base pairs (CTCT) at 1228 nucleotide position. Both the variations were predicted to be unstable or non-functional due to early premature termination codon (PTC) that would undergo mechanism of nonsense mediated decay (NMD) [32-34].

In family F2, both affected probands were homozygous for deletion of 15bp (c.1525_1539del15) resulting in an in-frame deletion of five amino acids (p.Val509_Tyr513del) (Figure 3B). This mutation is previously reported with a different nomenclature (c.1522_1536del15 (p.Tyr508_Leu512del)) and was predicted to produce a protein of shorter length.

In family F3, both the probands were compound heterozygous for c.2070C>G (p.Cys690Trp), and c.2380G>A (p.Glu794Lys) pathogenic variants (Figure 3C). These missense pathogenic variations are unique to the family and are predicted to be deleterious by in silico tools (Table 2).

In family F4, All the 3 probands of this family were homozygous for a novel single base pair deletion (c.877delC, p.Leu293CysfsTer11) (Figure 3D). The deletion of one base pair result in frameshift with the occurrence of an early stop codon (11 amino acids downstream). This further leads to formation of truncated protein which is expected to undergo NMD.

In family F5, a novel heterozygous missense change, (c.2632G>A, p.Ala878Thr) was identified in the affected proband (Figure 3E). This

![Figure 4: Representation of the structure of WFS1 gene comprising of 8 exons (exon 1 is non-coding), showing the mutations identified in this study. Different types of mutations are shown with dissimilar shaded boxes.](image)

| Family | Age/ Sex | Age of onset | Clinical details | Mutation identified | Protein change | Exon | Zygosity | Final Diagnosis |
|--------|----------|-------------|------------------|--------------------|----------------|------|----------|----------------|
| F1:P1  | 25-9-09/M | 7.5y        | DM, OA, HL, DI absent | c.2265T>A*, c.1228_1231delCTCT | p.Cys755Ter*, p.Val412SersTer29 | 8    | Compound Heterozygous | AR-WS |
| F1:P2  | 03-3-12/M | 5y          | DM, OA, HL, DI absent | c.2265T>A, c.1228_1231delCTCT | p.Cys755Ter, p.Val412SersTer30 | 8    | Compound Heterozygous | AR-WS |
| F2:P1  | 22Y/M   | 20y         | DI, DM, HL, OA    | c.1525_1539del15   | p.Val509_Tyr513del | 8    | Homozygous | AR-WS |
| F2:P2  | 12Y/M   | 12y         | DI, DM, HL, OA    | c.1525_1539del15   | p.Val509_Tyr513del | 8    | Homozygous | AR-WS |
| F3:P1  | 20Y/F   | 20y         | DI, DM, HL, OA    | c.2070C>G*, c.2380G>A* | p.Cys690Trp*, p.Glu794Lys* | 8    | Compound Heterozygous | AR-WS |
| F3:P2  | 22Y/M   | 22y         | DI, DM, HL, OA    | c.2070C>G, c.2380G>A | p.Cys690Trp; p.Glu794Lys | 8    | Compound Heterozygous | AR-WS |
| F4:P1  | 19Y/F   | 5y          | DI, DM, HL, OA    | c.877_877delC*      | p.Leu293CysfsTer11* | 8    | Homozygous | AR-WS |
| F4:P2  | 18Y/M   | 5y          | DI, DM, HL, OA    | c.877_877delC       | p.Leu293CysfsTer11 | 8    | Homozygous | AR-WS |
| F4:P3  | 15Y/F   | 5y          | DI, DM, HL, OA    | c.877_877delC       | p.Leu293CysfsTer11 | 8    | Homozygous | AR-WS |
| F5     | 28-12-11/M | 5y     | HL, OA absent, DM not present | c.2632G>A* | p.Ala878Thr* | 8    | Heterozygous | AD-LFNSHL |
| F6     | 7y/F    | 7y          | HL, OA absent, DM not present | c.2141A>C | p.Asn714Thr | 8    | Heterozygous | AD-LFNSHL |

*Novel mutations identified in this study, HL: Hearing Loss, OA: Optical Atrophy, DM: Diabetes Mellitus, AR-WS: Autosomal Recessive Wolfram Syndrome, AD-LFNSHL: Autosomal Dominant Low Frequency Non-Syndromic Hearing Loss

Table 1: Clinical and molecular data of the families with WS.
mutation is predicted to be deleterious by bioinformatic softwares (Table 2).

In family F6, a previously reported missense mutation, c.2141A>C (p.Asn714Thr) was noted (rs3975179196), unpublished data from Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine, reported in ClinVar). Based on computational analysis, the variant has been classified as pathogenic.

**Discussion**

Genetic studies in six Asian Indian families with WS identified biallelic mutation in WFS1 gene in 9 patients from 4 families, and heterozygous mutations in 2 patients with AD-LFSNHL. Only a few clinical reports describe phenotype of patients with WFS from India [35-39]. To the best of our knowledge, only one case of WS has been published mentioning homozygous mutation in exon 8 of the WFS1 gene [23].

In autosomal recessive Wolfram syndrome (AR-WS), 268 different mutations in WFS1 gene have been reported in HGD public database and more than 90% of WS patients carry mutations that result in a loss of function of the wolframin protein [34,40]. Majority of these pathogenic variants reside in exon 8 coding for transmembrane domain and C-terminal domain of wolframin protein [1,34,41-43]. In this study, all the pathogenic variants were identified in exon 8, suggesting that this is a mutational hotspot (Figure 4). This exon covers almost half portion of the gene coding for the functionally relevant region of protein (transmembrane domain and C-terminal domain) and thus inactivating mutations in this region result in disease phenotype.

In autosomal dominant low frequency sensorineural hearing loss (AD-LFSNHL) majority of variations observed are missense in exon 8 of WFS1 gene [1]. The present study showed comparable findings, with 2 missense variations in exon 8 identified in patients with hearing loss. Exon 8 of WFS1 gene contains the conserved C-terminal domain which has a crucial function in the cochlea. A mutation in this region of the gene is likely to cause hearing loss by affecting the regulation of inner ear homeostasis [42]. WS like syndrome is associated with autosomal dominant inherited hearing loss with/without optical atrophy and/or diabetes mellitus [6,14,15,44]. In addition, some WFS1 variations are known to cause type 1 and 2 DM and psychiatric problems [7,9,16]. Our patients had only hearing loss but no eye involvement or diabetes mellitus.

Eight mutations were identified in 11 probands of 6 different families with WS. Five of the 8 mutations were novel, observed for the first time in patients with WS. All missense mutations c.2070G>G (p.Cys690Trp), c.2380G>A (p.Glu794Lys), c.2632G>A (p.Ala878Thr) except c.2141A>C (p.Asn714Thr), 1 deletion mutation, c.877delC (p.Leu293CysfsTer11), and 1 nonsense mutation, c.2265T>A (p.Cys755Ter) were noted to be novel. Nonsense and missense pathogenic variants were present in the C-terminal domain of wolframin protein. These novel variants were checked for the pathogenicity using bioinformatics prediction tools and were found to be deleterious. Nonsense mutation, c.2265T>A (p.Cys755Ter), results in formation of truncated protein with a deletion of half of the C-terminal segment. This region is highly conserved across species and seems to have crucial function in the wolframin protein. It is speculated that this domain is interacting with some other unknown proteins [34]. Deletion pathogenic variants, c.877delC (p.Leu293CysfsTer11) and c.1228_1231del (p.Val412SerfsTer29), causes shift in reading frame, leading to a stop codon at 11 and 29 positions downstream respectively, which results in formation of a truncated protein. This truncated protein is predicted to undergo the known phenomenon of nonsense mediated decay (NMD) or form unfunctional protein with half of the transmembrane and C-terminal region being deleted. Thus, it is predicted to be a severe mutation as no protein/or truncated protein will be formed [32,33]. Two of the five novel pathogenic variants (c.2380G>A (p.Glu794Lys) and c.2632G>A (p.Ala878Thr)) were present in dbSNP database but have not been correlated with the disease phenotype of the WS patient (Table 2). Since we are associating these mutations with the disease for the first time, we label these variations as novel.

Two pathogenic variants identified in the present study were previously reported. The variant c.1525_1539del was reported earlier with a different nomenclature of c.1522_1536del15 by Ouwland et al. (one patient was homozygous, and another patient was heterozygous) [33]. Another reported mutation, c.2141A>C is mentioned in ClinVar as pathogenic, identified in an Indian patient with hearing loss (unpublished data from Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine).

Few mutations are known to be frequent in certain regions; e.g., c.424_425ins16 is common in the Spanish population and variation c.1362_1377del16 is prevalent in Italian patients [45,46]. However, no frequent mutation has been observed in the present case series. All the patients in this study harboured different mutations.

Wolframin protein is an ER membrane protein with nine transmembrane domains. It has a C-terminal domain located in ER lumen and N-terminal domain present in cytoplasm. The 9 transmembrane segment, forms loops facing both side of ER membrane (Figure 1) [17]. Wolframin protein’s C-terminal and transmembrane domain interact with Na/K ATPase b1 subunit in the inner ear. Therefore, mutations in any of these segments result in alteration of K+ circulation resulting in hearing loss [1,17]. In the present study 5 mutations were in the C-terminal domain and 3 mutations were in the transmembrane region of the protein, leading to deafness as a common symptom in this cohort (both AR-WS and AD-LFSNHL).
Wolframin is highly expressed in β cells of pancreas and may help in maturation of proinsulin to insulin that controls blood glucose levels. Thus, inactivating mutations lead to deficient level of this protein, which explains the occurrence of diabetes mellitus in these patients. Apart from the inactivating mutations, missense mutations in the C-terminal domain of the protein could also cause diabetes mellitus in these probands as it is an important segment for the proper functioning of the protein. It is also reported that a mutation in any of the last seven amino acids leads to a severe disease phenotype underlying the main role of this region in the protein [1]. Seven probands of 3 families (F1, F2 and F4) had inactivating mutations and two probands of 1 family (F3) having missense mutations had impairment of glucose regulation.

Two patients with AD-LFNSHL also had mutations in the C-terminal domain but these patients did not have diabetes mellitus. The reason of this could be that the mutations responsible for LFNSHL do not inactivate the WFS1 protein. These mutations have an altered gene product that opposes the wild-type allele, and thus, these mutations are presumed to have a dominant negative effect on the normal protein [47].

Wolframin is abundant in retinal cells and deficiency of this protein ultimately leads to optical atrophy [1,48]. We predict that the probands with AR-IWS having deleterious mutations result in deficient protein leading to optic atrophy. Patients with AD-LFNSHL do not have optic atrophy, as these are not loss of function mutations and thus have an antimorphic effect on normal protein.

Genotype could not be correlated with phenotype as the patient cohort is small. However, the findings in the present study are similar to those reported the literature that loss-of-function mutations such as terminations and deletions result in severe phenotype [22,32]. It is reported that compound heterozygosity for 2 missense mutations may cause milder phenotype [22,33]. In contrast, 2 probands of family (F3) in the present cohort had 2 different missense mutations, but they have all the severe features of Wolfram syndrome (DM, DI, HL and OA).

Conclusion

In conclusion, mutations in WFS1 gene can lead to autosomal recessive WS as well as autosomal dominant LFNSHL. Most of the mutations were present in transmembrane and C-terminal domain of wolframin making it an important segment for the functioning of the protein. All the mutations identified in the present cohort are located in exon 8 of WFS1 gene making it a hotspot region. We recommend a protocol in which WS patients should be first screened for the hotspot exon 8, and if no mutation is identified then the full gene should be sequenced. This study adds to the molecular data on WS from India. Further, patients with hearing loss with/without diabetes and or optical atrophy should be considered as one of the differentials for diagnosis of WS.

Declaration of Interest

All the authors declare that there is no conflict of interest with regards to preparation and submission of the manuscript.

Funding

There was no source of funding for the study.

Author contribution statement (optional):

DG, PB: Study design; DG, PB, SBM, RDP, LD, AB, ICV: Patient contribution and clinical details analysis; DG, PB, RS: Molecular studies and data analysis; DG, PB: Manuscript preparation; RS, ICV: Critical analysis for important intellectual content.

Acknowledgements

We thank our colleagues at Institute of Medical Genetics and Genomics and to patients whom contributed in this study.

References

1. Rigoli L, Lombardo F, Di-Bella C (2011) Wolfram syndrome and WFS1 gene. Clin Genet 79: 103-117.
2. Bueno GE, Ruiz-Castañeda D, Martinez JR, Munoz MR, Alasico PC (2018) Natural history and clinical characteristics of 50 patients with Wolfram syndrome. Endocrine 61: 440-446.
3. Fraser FC, Gunn T (1977) Diabetes mellitus, diabetes insipidus, and optic atrophy: An autosomal recessive syndrome. J Med Genet 14: 190-193.
4. Barrett TG, Bundey SE, Macleod AF (1995) Neurodegeneration and diabetes: UK nationwide study of Wolfram. Lancet 346: 1458-1463.
5. Strom TM, Hörtegal K, Hofmann S, Gekeler F, Scharfe C, et al. (1998) Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (Wolframin) coding for a predicted transmembrane protein. Hum Mol Genet 7: 2021-2028.
6. Rendtorff ND, Lodahl M, Boulahbel H, Johansen IR, Pandya A, et al. (2011) Identification of p.A684V missense mutation in the WFS1 gene as a frequent cause of autosomal dominant optic atrophy and hearing impairment. Am J Med Genet 155: 1298-1313.
7. Bonnycastle LL, Chines PS, Hara T, Huyghue JR, Swift AJ, et al. (2013) Autosomal dominant diabetes arising from a Wolfram syndrome 1 mutation. Diabetes 62: 3943-3950.
8. Bespalova IN, Van-Camp G, Born SJ, Brown DJ, Cryns K, et al. (2001) Mutations in the Wolfram syndrome 1 gene (WFS1) are a common cause of low frequency sensorineural hearing loss. Hum Mol Genet 10: 2501-2508.
9. Sandhu MS, Weedon MN, Fawcett KA, Wasson J, Debenham SL, et al. (2007) Common variants in WFS1 confer risk of type 2 diabetes. Nature Genet 39: 951-953.
10. Maltoni G, Minardi R, Cristalli CP, Nardi L, D’Alberto F, et al. (2016) A novel compound heterozygous mutation in an adolescent with insulin-dependent diabetes: The challenge of characterizing Wolfram syndrome. Diab Res Clin Pract 121: 59-61.
11. Galvez-Ruiz A, Galindo-Ferreiro A, Schatz P (2017) Genetic testing for wolfram syndrome mutations in a sample of 71 patients with hereditary optic neuropathy and negative genetic test results for OPA1/OPA3/LHON. Neuroophthalmology 37: 394-397.
12. Çelmeği M, Türkükkıranım D, Çürek Y, Houghton J, Akgürin S, et al. (2017) Clinical and molecular genetic analysis in three children with wolfram syndrome: A novel wfs1 mutation (c.2534T>A). J Clin Res Pediatr Endocrinol 9: 30-34.
13. Duan L, Li Q, Tong AL, Mao JF, Yu M, et al. (2018) Clinical characteristics of wolfram syndrome in chinese population and a novel frameshift mutation in WFS1. Front Endocrinol 9: 18.
14. Elberg H, Hansen L, Kjer B, Hansen T, Pedersen O, et al. (2006) Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 gene. J Med Genet 43: 435-440.
15. Hogewind BF, Pennings RJ, Hol FA, Kunst HP, Hoefsloot EH, et al. (2010) Autosomal dominant optic neuropathy and sensorineural hearing loss associated with a novel mutation of WFS1. Mol Vision 16: 26-35.
16. Kawamoto T, Horikawa Y, Tanaka T, Kabe N, Takeda J, et al. (2004) Genetic variations in the WFS1 gene in Japanese with type 2 diabetes and bipolar disorder. Mol Genet Metab 82: 238-245.
17. Zatlky M, Rickells C, Da Silva Xavier G, Minton J, Fenton S, et al. (2008) Sodium-potassium ATPase 1 subunit is a molecular partner of Wolframin, an endoplasmic reticulum protein involved in ER stress. Hum Mol Genet 17: 190-200.
18. Yurimoto S, Hatano N, Tsuichiya M, Kato K, Fujimoto T, et al. (2009) Identification and characterization of Wolframin, the product of the Wolfram syndrome gene (WFS1), as a novel calmodulin-binding protein. Biochim Biophys Acta 1792: 3946-3955.
19. Fonseca SG, Ishigaki S, Olsowski CM, Lu S, Lipson KL, et al. (2010) Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest 120: 744-755.

20. Hatanaka M, Tanabe K, Yanai A, Ohta Y, Kondo M, et al. (2011) Wolfram syndrome 1 gene (WFS1) product localizes to secretory granules and determines granule acidification in pancreatic beta-cells. Hum Mol Genet 20: 1274-1284.

21. Fonseca SG, Uruno F, Weir GC, Gromada J, Burcin M (2012) Wolfram syndrome 1 and adenyl cyclase 8 interact at the plasma membrane to regulate insulin secretion and secretion. Nature Cell Biol 14: 1105-1112.

22. Hofmann S, Philbrook C, Gerbilz KD, Bauer MF (2003) Wolfram syndrome: Structural and functional analyses of mutant and wild-type wolframin, the WFS1 gene product. Hum Mol Genet 12: 2003-2012.

23. Kesavadev J, Kumar A, Shankar A, Gopalakrishnan G, Permutt MA, et al. (2011) An Asian Indian woman with Wolfram syndrome on insulin pump: Successful pregnancy and beyond. Diab Technol Therap 13: 781-785.

24. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res 16: 1215.

25. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nature Meth 7: 248-249.

26. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-3814.

27. Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) Mutation Taster 2: Mutation prediction for the deep-sequencing age. Nature Meth 11: 366-369.

28. Chun S, Fay JC (2009) Identification of deleterious mutations within three human genomes. Genome Res 19: 1563-1564.

29. Reva BA, Antipin YA, Sander C (2007) Determinants of protein function and mechanistic variations across species. Curr Opin Cell Biol 17: 316-325.

30. Shihab HA, Rogers MF, Gough J, Mort M, Cooper DN, et al. (2015) An integrative approach to predicting the functional consequences of non-coding and coding sequence variation. Bioinform 31: 1536-1543.

31. Sievers F, Wilm A, Dineen DG, Gibson TJ, Karplus K, et al. (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Sys Biol 7: 539.

32. Smith CJ, Crock PA, King BR, Meldrum CJ, Scott RJ (2004) Phenotype-genotype correlations in a series of wolframp syndrome families. Diab Care 27: 2003-2009.

33. Conti E, Izaularde E (2005) Nonsense-mediated mRNA decay: Molecular insights and mechanistic variations across species. Curr Opin Cell Biol 17: 316-325.

34. Van-Ven Ouweland JM, Cryns K, Pennings RJ, Walraven I, Janssen GM, et al. (2003) Molecular characterization of WFS1 in patients with Wolfram syndrome. J Mol Diag 5: 88-95.

35. Viswanathan V, Medempudi S, Kadri M (2008) Wolfram Syndrome. J Assoc Physi India 56: 197-199.

36. Ganie MA, Laway BA, Nisar S, Wani MM, Khurana ML, et al. (2011) Presentation and clinical course of Wolfram (Diabetes Insipidus, Myelopathy, Optic atrophy, Deafness) syndrome from North India. Diab Med 28: 1337-1342.

37. Saran S, Philip R, Patidar P, Gutch M, Agroiya P, et al. (2012) Atypical presentations of Wolframs syndrome. Indian J Endocrinol Metab 16: S504-S505.

38. Satyarthi GD (2016) Commentary: Wolfram (DiDiMOAD) syndrome: A progressive disorder with non-synchronized clinical and imaging features. Neurol India 64: 1312-1313.

39. Harsha KJ, Wolfram PK (2016) Wolfram (DiDiMOAD) syndrome with ventral central pontine hyperintensity without brainstem atrophy. Neurol India 64: 1310-1312.

40. Stenson PD, Mort M, Ball EV, Shaw K, Phillips AD, et al. (2014) The human gene mutation database: Building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133: 1-9.

41. Tessa A, Carbone I, Matteoli MC, Bruno C, Patrino C, et al. (2001) Identification of novel WFS1 mutations in Italian children with Wolfram syndrome. Hum Mutat 17: 348-349.

42. Cryns K, Sivakumaran TA, Van Den Ouweland JM, Pennings RJ, Cremers CW, et al. (2003) Mutational spectrum of the WFS1 gene in Wolfram syndrome, non-syndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Genet 22: 275-287.

43. Hansen L, Eiberg H, Barrett T, Bek T, Kjaersgaard P, et al. (2005) Mutation analysis of the WFS1 gene in seven Danish Wolfram syndrome families: Four new mutations identified. Eur J Hum Genet 13: 1275-1284.

44. Young TL, Ives E, Lynch E, Person R, Snook S, et al. (2001) Non-syndromic progressive hearing loss DFNA38 is caused by heterozygous missense mutation in the wolframp syndrome gene WFS1. Hum Mol Genet 10: 2509-2514.

45. Gómez-Zaera M, Strom TM, Rodríguez B, Estivill X, Meitinger T, et al. (2001) Presence of a major WFS1 mutation in Spanish Wolfram syndrome pedigrees. Mol Genet Metab 72: 72-81.

46. Colosimo A, Guida V, Rigoli L, Di Bella C, De Luca A, et al. (2003) Molecular detection of novel WFS1 mutations in patients with Wolfram syndrome by a DHPLC-based assay. Hum Mutat 21: 622-623.

47. Morikawa S, Tajima T, Nakamura A, Ishizu K, Ariga T (2017) A novel heterozygous mutation of the WFS1 gene leading to constitutive endoplasmic reticulum stress is the cause of Wolfram syndrome. Pediatr Diab 18: 934-941.

48. Rigoli L, Bramanti P, Di Bella C, De Luca F (2018) Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res 83: 921-929.